A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)

Trial Profile

A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)

Suspended
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Daratumumab; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 15 Sep 2017 According to a Roche media release, based on emerging safety data from clinical trials evaluating pembrolizumab with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib (NCT02431208) and a Phase Ib/II TECENTRIQ study (NCT02631577) be placed on partial clinical hold.Patients who are currently enrolled in these trials and who are deriving clinical benefit may continue to receive treatment, but no additional patients will be enrolled in these trials.
    • 15 Sep 2017 Status changed from recruiting to suspended, according to a Roche media release.
    • 21 Aug 2017 Planned End Date changed from 27 Aug 2019 to 26 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top